Navigation Links
BiOptix to highlight new 404pi instrument at European symposia
Date:11/1/2012

BOULDER, Colo., AMSTERDAM and VIENNA, Nov. 1, 2012 /PRNewswire/ -- BiOptix today announced that it would be highlighting the new BiOptix 404pi, the first commercially available SPR instrument to incorporate phase-based common path interferometry technology, at the Label Free Technologies Show in Amsterdam from November 1 - 3 as well as at the PEGS Europe Summit on November 6 – 8. 

"At the Label Free and PEGS Europe meetings, BiOptix will unveil new application data that demonstrates the value proposition of the upcoming BiOptix 404pi," noted Ken Wilczek, Vice President of Sales & Marketing for BiOptix.  "We are excited to demonstrate how BiOptix Enhanced or Phase-based SPR differs from standard surface plasmon resonance detection methods in that BiOptix technology combines the high sensitivity of SPR with the high stability and lower noise of common path interferometry—utilizing an internal reference for increased sensitivity."

BiOptix technology allows for the simultaneous monitoring of multiple analytes in a single sample.  This new class of SPR instrumentation from BiOptix has been designed to measure protein/protein and protein-small molecule interactions (down to 100 Da) in a high-throughput 96/384 well platform utilizing 4 parallel channels rather than a single flow cell.     

Surface Plasmon Resonance is an advanced and highly sensitive optical technology that can measure refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.

About BiOptix

BiOptix Diagnostics Corporation is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures and Rusnano.  BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at:  www.bioptix.com


'/>"/>
SOURCE BiOptix
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. BiOptix Participates in Leading Life Sciences Event BioWest 2012
2. BiOptix announces expansion of Board of Directors
3. AGU journal highlights -- 31 August 2012
4. Biomass characterization technology research highlighted in Industrial Biotechnology journal
5. Genetics Society of America’s GENETICS journal highlights for August 2012
6. AGU journal highlights -- 31 July 2012
7. New video series highlights the people who fuel Americas innovation pipeline
8. AGU Journal highlights -- July 16
9. Differences between human twins at birth highlight importance of intrauterine environment
10. Genetics Society of Americas Genetics journal highlights for July 2012
11. Highlighting molecular clues to the link between childhood maltreatment and later suicide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
Breaking Biology News(10 mins):
(Date:5/21/2017)... ... May 19, 2017 , ... Ovation Fertility scientists’ work ... Association of Bioanalysts (AAB) and the College of Reproductive Biology (CRB) today and ... commitment to excellence in clinical laboratory services and regulations. , “We are ...
(Date:5/19/2017)... ... May 19, 2017 , ... The University ... researchers with technologies ripe for commercialization, and who are affiliated with the 21 ... to submit proposals. QED, now in its tenth round, is the first multi-institutional ...
(Date:5/18/2017)... ... ... Clinical Supplies Management (“CSM”), a Great Point Partners II (“GPP”) portfolio company, today announced ... in size over the past six months with the acquisition of businesses in Belgium ... as Chief Financial Officer. Roger has over 25 years of experience in finance ...
(Date:5/18/2017)... ... 17, 2017 , ... Cognition Corporation ( http://www.cognition.us ... released version 9.0 of the Cognition Cockpit platform. , “Our whole team has ... Cronin, CEO of Cognition. “We’re thrilled to finally be able to release it ...
Breaking Biology Technology: